Abstract
Objective Psychiatric polygenic risk scores (PRS) have the potential to transform aspects of psychiatric care and prevention, but there are concerns about their implementation. We sought to assess child and adolescent psychiatrists’ (CAP) experiences, perspectives, and potential uses of psychiatric PRS.
Methods A survey of 960 US-based practicing CAP.
Results Most respondents (54%) believed psychiatric PRS are currently at least slightly useful and 87% believed they will be so in five years. Yet, 77% rated their knowledge of PRS as poor or very poor. Ten percent have had a patient/family bring PRS to them, and 25% would request PRS if a patient/caregiver asked. Respondents endorsed different actions in response to a hypothetical child with a top 5th percentile psychiatric PRS but no diagnosis: 48% would increase prospective monitoring of symptoms, 42% would evaluate for current symptoms, and 4% would prescribe medications. Most respondents were concerned that high PRS results could lead to overtreatment and negatively impact patients’ emotional well-being.
Conclusion Findings indicate emerging use of psychiatric PRS within child and adolescent psychiatry in the US. Thus, it is critical to examine the ethical and clinical challenges that PRS may generate and begin efforts to promote their informed and responsible use.
Competing Interest Statement
Dr. Pereira reports research grants from the NIH. Ms. Munoz reports no biomedical financial interests or potential conflicts of interest. Dr. Small reports no biomedical financial interests or potential conflicts of interest. Dr. Soda reports research grants from the NIH and the Foundation of Hope for Research and Treatment of Mental Illness. Ms. Torgerson reports no biomedical financial interests or potential conflicts of interest. Ms. Sanchez reports no biomedical financial interests or potential conflicts of interest. Dr. Austin reports research grants (unrelated to this work) from the Canadian Institutes of Health Research, NIH, Pfizer, and Genome BC, and is supported by the Canada Research Chairs Program and BC mental health and substance use services. Dr. Storch receives research support from NIH, Texas Higher Education Coordinating Board, Houston Community Foundation and Ream Foundation. He receives book royalties from Elsevier, Wiley, Oxford, Springer, Jessica Kingsley, and American Psychological Association. He is a consultant for Biohaven Pharmaceuticals and owns stock in NView. Dr. Lazaro-Munoz reports research grants from the NIH.
Funding Statement
This work was funded by the National Human Genome Research Institute and the National Institute of Mental Health of the National Institutes of Health, grants R00HG008689 (Lazaro-Munoz), 3R00HG008689-05S1 (Lazaro-Munoz, Storch), R01MH128676 (Pereira, Lazaro-Munoz, Storch), and P50HD103555 (Storch) for use of the Clinical and Translational Core facilities. The views expressed are those of the authors alone, and do not necessarily reflect views of NIH, Baylor College of Medicine, or Harvard Medical School.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Baylor College of Medicine Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
